Hyderabad-based Aurobindo Pharma has today announced that the company has received an approval from Canada for its antibiotic drug. The drug is called Cefuroxime Axetil Tablets, and is the generic version of GlaxoSmithKline's Ceftin Tablets. Aurobindo has received approval to market 250 mg and 500 mg versions of the drug. Ceftin Tablets is used to treat patients with mild to moderate infections.
This is Aurobiondo's eighth approval from Health Canada. The company has a wide-spread international presence and markets its products across 125 countries. Its manufacturing facilities are approved by various regulatory agencies from US, Canada, Brazil and South Africa.
Aurobindo manufactures both generic medicines and active pharmaceutical ingredients. Apart from antibiotics, Aurobindo has products across different areas of medicine like anti-retrovirals, anti-allergins, gastro-enterologicals, cardiovascular drugs.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
